Shares will likely trade near the $31.50 offer price with a small spread reflecting regulatory and shareholder approval risk. The stock could trade at a slight discount until the shareholder vote and HSR clearance are obtained. Traders should monitor the proxy filing and regulatory calendar for closing timeline updates.
CPRX drugs
CPRX drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+20- T+0 · May 7 $31.17entry
- T+1 · 6mo ago −0.06%α −0.89% · $31.15
- T+5 · 6mo ago −0.03%α −1.54% · $31.16
- T+20 · 6mo ago +0.35%α −2.78% · $31.28
- T+60 · due 4mo ago Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Catalyst Pharmaceuticals (CPRX) has entered into a definitive agreement to be acquired by Angelini Pharma for $31.50 per share in cash, representing a total equity value of approximately $4.1 billion. The price reflects a 28% premium to the 30-day volume-weighted average price. Separately, Catalyst resolved all remaining FIRDAPSE patent litigation, with Hetero agreeing not to launch a generic version before January 2035, strengthening the IP outlook for the flagship product.
Key Financial Metrics
Key Facts
- Acquisition price: $31.50 per share in cash
- Total equity value: ~$4.1 billion
- Premium: 28% to unaffected 30-day VWAP as of April 22, 2026
- Expected closing: Q3 2026
- Transaction not subject to financing condition
- Boards of both companies unanimously approved
- Termination fee payable by Catalyst: $155.5 million
- Patent settlement with Hetero pushes generic FIRDAPSE entry to at least January 2035
- All directors and executive officers entered into voting agreements to support the deal
Financial Impact
Stockholders to receive $31.50 per share in cash, totaling approximately $4.1 billion equity value
Risk Factors
- Failure to obtain required regulatory approvals (HSR Act)
- Shareholder vote fails to adopt the merger agreement
- Superior proposal triggers termination and $155.5M break fee
- Material adverse effect between signing and closing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 9 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-210518 |
| Document: d90722d8k.htm | 0001193125-26-210518 |
| Document: d90722dex101.htm | 0001193125-26-210518 |
| Document: d90722dex991.htm | 0001193125-26-210518 |
| Document: d90722dex992.htm | 0001193125-26-210518 |
| Document: d90722dex31.htm | 0001193125-26-210518 |
| Document: 0001193125-26-210518-index-headers.html | 0001193125-26-210518 |
| Document: 0001193125-26-210518-index.html | 0001193125-26-210518 |
| Document: 0001193125-26-210518.txt | 0001193125-26-210518 |
Track record
16 reports on CPRX
3 of 5 bullish or bearish reports moved the stock their way by T+20. Best: +25.72% at T+60 after the Feb 25, 2026 report. 5 of 8 went positive at some point.
Filters
- Nov 4, 202612d ago Institutional Cluster Bearish 4/10 No price data
- Aug 22, 202612w ago Institutional Cluster Mixed 5/10 No price data
- Jul 24, 202616w ago 15-12G Bearish 9/10 Entry $31.49 No price data
- Jul 17, 202617w ago EFFECT Bearish 5/10 Entry $31.49 No price data
- Jul 15, 202617w ago 25-NSE Bearish 9/10 Entry $31.49 No price data
- Jul 8, 202618w ago 8-K Bullish 6/10 Entry $31.47 No price data
- Jun 30, 202619w ago DEFA14A Neutral 3/10 Entry $31.44 No price data
- Jun 30, 202619w ago 8-K Neutral 4/10 Entry $31.44 No price data
- May 28, 202624w ago PREM14A Bullish 8/10 Entry $31.23 to $31.46 ▲ +0.74% +2.53% vs SPY
- May 12, 202626w ago DEFA14A Neutral 3/10 Entry $31.14 to $31.34 ▲ +0.64% +2.37% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers